Jasmiel is a combination oral contraceptive comprising drospirenone (3 mg) and ethinyl estradiol (0.02 mg). It is indicated for preventing pregnancy and managing moderate acne and premenstrual dysphoric disorder (PMDD) in females of reproductive potential who choose to use an oral contraceptive for contraception. (DailyMed)
Pharmacological Profile
- Active Ingredients: Drospirenone, a synthetic progestin with anti-mineralocorticoid properties, and ethinyl estradiol, a synthetic estrogen.
- Mechanism of Action: Inhibits ovulation, thickens cervical mucus, and alters the endometrial lining to prevent pregnancy. (DailyMed)
Indications
- Contraception: Primary indication for preventing pregnancy.
- Moderate Acne: For females at least 14 years old who have started menstruation and desire contraception.
- PMDD: For females of reproductive potential who choose an oral contraceptive for contraception. (DailyMed)
Dosage and Administration
- Regimen: 28-day cycle consisting of 24 active tablets (light pink to pink) and 4 placebo tablets (green).
- Starting Method: Can begin on the first day of menstruation (Day 1 Start) or the first Sunday after menstruation begins (Sunday Start).
- Missed Doses: If one active tablet is missed, take it as soon as remembered and continue the regimen. If two consecutive active tablets are missed, take two tablets as soon as possible and two the next day, then continue with one tablet daily. Additional non-hormonal contraception should be used if tablets are missed during the first 7 days of a new pack. (Drugs.com)
Contraindications
- Absolute: History of thromboembolic disorders, stroke, myocardial infarction, uncontrolled hypertension, liver disease, breast cancer, and known or suspected pregnancy.
- Relative: Women over 35 who smoke, as smoking increases the risk of serious cardiovascular events. (DailyMed)
Warnings and Precautions
- Cardiovascular Risks: Increased risk of thromboembolic events, especially in the first 6 months of use.
- Hyperkalemia: Drospirenone has anti-mineralocorticoid activity; monitor serum potassium levels in patients using concomitant potassium-sparing medications. (DailyMed)
- Liver Function: Discontinue if jaundice or other signs of liver dysfunction occur.
- Surgical Considerations: Discontinue at least 4 weeks before major surgery and resume no earlier than 2 weeks post-surgery.
Adverse Reactions
- Common: Nausea, headache, breast tenderness, weight gain, mood changes, and menstrual irregularities.
- Serious: Signs of thromboembolic events (e.g., sudden numbness, chest pain, shortness of breath), liver dysfunction (e.g., jaundice), and visual disturbances.
Drug Interactions
- Contraindicated: Concomitant use with hepatitis C antiviral combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to potential liver enzyme elevation. (DailyMed)
- Caution: Antibiotics (e.g., rifampin), anticonvulsants, and certain antifungals may reduce efficacy.
Use in Specific Populations
- Pregnancy: Contraindicated.
- Lactation: May reduce milk production; consider alternative contraception methods.
- Pediatric Use: Safety and efficacy not established in females under 14 years of age.
Conclusion
Jasmiel is an effective oral contraceptive option for females seeking pregnancy prevention, with additional benefits for managing moderate acne and PMDD. Its use requires careful consideration of individual health profiles and potential risks. Patients should consult healthcare providers to determine appropriateness and receive guidance on proper administration.
Leave a Comment